Engage Bio

Current gene therapies often rely on viral vectors that can be hard to manufacture at scale, have limited durability, and may not be safely redosable.

Engage Bio develops Tethosomes, a non-viral DNA delivery platform for potent, durable, redosable, and scalable genetic medicines.

Biopharmaceutical companies and clinical researchers developing and delivering gene therapies.